Safety data for adalimumab therapy for plaque psoriasis in children is derived from studies in adults, which undercores the need for dedicated pediatric research.
Amgen announced positive topline results from the phase 3 study of apremilast (Otezla®), a phosphodiesterase 4 (PDE4) inhibitor, for the treatment of adults with mild to moderate plaque psoriasis.
Researchers conducted cost-effectiveness analyses to compare ixekizumab and secukinumab in psoriatic arthritis and moderate to severe plaque psoriasis.
Ustekinumab, secukinumab, and ixekizumab were compared for clinical effectiveness and associated adverse events in the treatment of plaque psoriasis.
Comparative safety data in real-life settings from 9 psoriasis treatments could aid clinicians in selecting the most appropriate treatments for their patients.
A subset of patients at risk for Alzheimer disease because of systemic inflammation may benefit from receiving a tumor necrosis factor (TNF) blocking agent.
A large-scale study assesses the risk for serious infection and hospitalization in patients with psoriasis.
A novel study assesses the safety and efficacy of apremilast in patients with psoriasis and evaluates the treatment as a metabolic modulator.
New registries have been established to capture emerging data on patients with psoriasis and atopic dermatitis who have COVID-19.
A study from Italy reports severe outcomes related to the COVID-19 infection in patients with chronic plaque psoriasis receiving immunosuppressive therapies.